Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB2015-LR risk-adapted treatment stratification in low- and intermediate-risk neuroblastoma
2017-004883-37Phase 3Active
- Sponsor
- University of Cologne
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of busulfan, carboplatin, cisplatin, cyclophosphamide, dacarbazine and 8 more in neuroblastoma, sponsored by University of Cologne. Primary endpoint: Event-free survival. Started Sep 2020; status: active.
02
Drugs
busulfancarboplatincisplatincyclophosphamidedacarbazine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2017-004883-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004883-37.